Sustained Benefit for Newly Approved Myasthenia Gravis Drug Sustained Benefit for Newly Approved Myasthenia Gravis Drug

Early responders to zilucoplan, the newly approved medication for myasthenia gravis have sustained benefit for up to 60 weeks, new analyses show.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news